Drug Eluting Stents Legal News Articles & Interviews

Washington, DC: Angioplasty was designed as a safe alternative to open heart surgery, but a procedure using balloon angioplasty devices called transvascular autonomic modulation (TVAM) is not safe, which the FDA has warned of repeatedly. Some doctors, however, believe its benefits outweigh the risks involved.


The agency in March 2017 issued a warning to patients with autonomic dysfunction (nervous system disorders), including Parkinson’s disease, multiple sclerosis (MS), fibromyalgia, multiple system atrophy and more, and doctors who use balloon angioplasty devices to treat them. TVAM has not been approved or formally studied and it could put patients at risk of serious complications. But one doctor continues to use the device “off-label”, saying the benefits of this procedure are “usually seen immediately.” He also treats Lyme disease with TVAM rather than antibiotics and explains it in a video.


In September 2016 the FDA put Dr. Arata of Newport Beach, California on notice by way of “Initiation of Disqualification Proceedings and Opportunity to Explain”

(NIDPOE), to determine whether he should be disqualified from receiving investigational products under FDA’s regulations. Arata claims the angioplasty TVAM procedure treats the signs and symptoms of autonomic dysfunction in some neurological disorders, but the FDA says it has no data to indicate such claims. Rather, the agency says that TVAM is an experimental treatment that has been associated with at least one death.


Back in May 2012, the FDA warned of the risks involved with a similar procedure. The same balloon angioplasty devices were used to treat chronic cerebrospinal venous insufficiency (CCSVI). Reports of serious complications included one patient who died from bleeding in the brain and another patient suffered permanent paralysis from a stroke after CCSVI treatment. Are doctors aware of the FDA reports regarding balloon angioplasty and choose to use the device off-label, potentially putting their patients at risk? The agency received a report after this 2012 warning that a balloon ruptured while being placed in a patient’s jugular vein. The device moved to the patient's lung, where it was surgically removed.


A warning letter (February 2012) was sent to Dr. Manish Mehta, whose practice in Albany, New York was investigated by the FDA. “The inspection was conducted under a program designed to ensure that data and information contained in requests for Investigational Device Exemptions (IDE), Premarket Approval applications, and Premarket Notification (510(k)) submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.” The agency found that Mehta had violated a clinical study by failing to submit correct documentation before patients were treated with the balloon angioplasty device.


Back to March 2017: Canadian researchers at the University of British Columbia and Vancouver Coastal Health reported results from a study that involved 104 patients with MS treated with angioplasty TVAM, according to the Associated Press. The patients did no better with TVAM than those without the procedure. And the FDA’s case against Arata is on hold: to be continued…

Dallas, TX The FDA is taking the unusual step of calling out a specific doctor and warning people to steer clear of the use of TVAM angioplasty as a treatment for serious illnesses such as Parkinson’s disease, Multiple Sclerosis and other autonomic disorders.

Washington, DC When the US Food and Drug Administration (FDA) approved 'Endeavor,' the drug-coated Medtronic stent earlier this year, it did so amidst a storm of controversy as to whether or not the stents promote potentially dire blood clots in heart attack patients. Drug eluting stents are still under FDA scrutiny, but as 2008 dawned there was little conclusive evidence to prove the suspicion as fact.

Washington, DC: The stenting for profit industry hit a major snag on March 1, 2007, when the US House Oversight and Government Reform Committee, ordered Johnson & Johnson and Boston Scientific to turn over documents related to their sales and marketing activities for drug-eluting stents.

Washington, DC: In addition to the federal investigations into the off-label marketing of drug eluting stents by Boston Scientific and Johnson & Johnson, on May 10, 2007, Rep Maurice Hinchey (D-NY), who serves on the House Appropriations Subcommittee, announced the introduction of the FDA reform bill which addresses the issue of doctors using products for unapproved uses, which usually occurs without the patient's knowledge or consent.

Washington DC The stenting for profit industry may soon be history. On March 1, 2007, the chairman of the US House Oversight and Government Reform Committee, Henry Waxman (D-CA), ordered Johnson & Johnson and Boston Scientific to turn over documents as part of an investigation into the off-label marketing of drug-eluting stents.